Chair
Member
Audit Committee Position

Richard Henriques, M.B.A.

Mr. Henriques joined Cabaletta’s Board of Directors in February 2019. Since 2015, he has been a senior fellow at the Center for High Impact Philanthropy at the University of Pennsylvania, with a focus on impact investing. From 2010 to 2014, Mr. Henriques was the chief financial officer of the Bill & Melinda Gates Foundation, where he was responsible for finance and accounting, financial planning and analysis, strategic planning, measurement and evaluation, program-related investments, and information technology. From 1981 to 2008, Mr. Henriques held positions at Merck & Co., Inc., including as Senior Vice President of Finance for Global Human Health, Vice President and Corporate Controller, and Principal Accounting Officer. Mr. Henriques also serves on the boards of directors of Emulate Therapeutics Inc. (formerly Nativis Inc.), Arbutus Biopharma Corporation, a public company, the Heritage Conservancy and Episcopal Community Services and on the board of trustees of the Franklin Institute.

Chair

Brian Daniels, M.D.

Dr. Daniels joined Cabaletta’s Board of Directors in October 2018. Since 2018, he has been a partner at 5AM Ventures, where he was previously a venture partner from 2014 to 2018. From 2004 to 2014, Dr. Daniels held positions at Bristol-Myers Squibb, serving as senior vice president, global development and medical affairs from 2004 to 2014. Dr. Daniels also serves on the boards of directors of Nohla Therapeutics Inc., and Novo Nordisk A/S, and on the clinical advisory board of Aprea Therapeutics AB. He previously served on the boards of directors of Spyryx Biosciences, Inc., RareCyte, Inc., and IDEAYA Biosciences, Inc. Dr. Daniels received his M.D. from Washington University in St. Louis and his B.S. and M.S. from Massachusetts Institute of Technology. He completed his residency in Internal Medicine at New York Hospital and a fellowship in Rheumatology and Immunology at the University of California, San Francisco.

Member

Mark Simon, M.B.A.

Mr. Simon joined Cabaletta’s Board of Directors in October 2018. He is a partner and co-founder of, and advisor to, Torreya Partners, LLC, a global investment banking firm serving companies in the life sciences industry. Prior to co-founding Torreya, Mr. Simon was a managing director and head of life sciences investment banking at Citigroup from 2002 to 2005, and a senior biotechnology research analyst at Robertson Stephens from 1989 to 2002. He began his career at Kidder Peabody. Mr. Simon is a strategic advisor to Sun Pharma Advanced Research Company Limited, a public company in India. Mr. Simon formerly served on the boards of directors of ControlRad Systems from 2012 to 2019 and Hutchinson Water International Holdings Limited from 2014 to 2018. Mr. Simon also serves on the board of several disease advocacy and philanthropic foundations. He received his M.B.A. from Harvard Business School and his B.A. from Columbia College.

Member

Audit Committee Charter

Download
Compensation Committee Position

Brian Daniels, M.D.

Dr. Daniels joined Cabaletta’s Board of Directors in October 2018. Since 2018, he has been a partner at 5AM Ventures, where he was previously a venture partner from 2014 to 2018. From 2004 to 2014, Dr. Daniels held positions at Bristol-Myers Squibb, serving as senior vice president, global development and medical affairs from 2004 to 2014. Dr. Daniels also serves on the boards of directors of Nohla Therapeutics Inc., and Novo Nordisk A/S, and on the clinical advisory board of Aprea Therapeutics AB. He previously served on the boards of directors of Spyryx Biosciences, Inc., RareCyte, Inc., and IDEAYA Biosciences, Inc. Dr. Daniels received his M.D. from Washington University in St. Louis and his B.S. and M.S. from Massachusetts Institute of Technology. He completed his residency in Internal Medicine at New York Hospital and a fellowship in Rheumatology and Immunology at the University of California, San Francisco.

Chair

Catherine Bollard, M.D.

Dr. Bollard joined Cabaletta’s Board of Directors in April 2019. She is the director of the Center for Cancer and Immunology Research at the Children’s Research Institute and the director of the Program for Cell Enhancement and Technologies for Immunotherapy at the Children’s National Health System, or CNH. She is also a faculty member of the Division of the Blood and Marrow Transplantation of CNH. Since 2013, Dr. Bollard also serves as Professor of Pediatrics and Microbiology, Immunology, and Tropical Medicine at George Washington University and is the associate center director for translational research and innovation within the George Washington Cancer Center. Prior to 2013, Dr. Bollard was Professor of Pediatrics, Medicine, and Immunology at Baylor College of Medicine. She is the immediate past president of the International Society for Cell Therapy, and she served on the Cellular, Tissues, and Gene Therapy Advisory Committee of the FDA until 2019. Dr. Bollard chaired the Non-Hodgkin’s Lymphoma Committee of the Children’s Oncology Group from 2012 to 2020 and in 2021 became the President of the Foundation for the Accreditation of Cellular Therapy. Dr. Bollard received her medical degree from the University of Otago Medical School in New Zealand.

Member

Mark Simon, M.B.A.

Mr. Simon joined Cabaletta’s Board of Directors in October 2018. He is a partner and co-founder of, and advisor to, Torreya Partners, LLC, a global investment banking firm serving companies in the life sciences industry. Prior to co-founding Torreya, Mr. Simon was a managing director and head of life sciences investment banking at Citigroup from 2002 to 2005, and a senior biotechnology research analyst at Robertson Stephens from 1989 to 2002. He began his career at Kidder Peabody. Mr. Simon is a strategic advisor to Sun Pharma Advanced Research Company Limited, a public company in India. Mr. Simon formerly served on the boards of directors of ControlRad Systems from 2012 to 2019 and Hutchinson Water International Holdings Limited from 2014 to 2018. Mr. Simon also serves on the board of several disease advocacy and philanthropic foundations. He received his M.B.A. from Harvard Business School and his B.A. from Columbia College.

Member

Compensation Committee Charter

Download
Nominating and Corporate Governance Committee Position

Mark Simon, M.B.A.

Mr. Simon joined Cabaletta’s Board of Directors in October 2018. He is a partner and co-founder of, and advisor to, Torreya Partners, LLC, a global investment banking firm serving companies in the life sciences industry. Prior to co-founding Torreya, Mr. Simon was a managing director and head of life sciences investment banking at Citigroup from 2002 to 2005, and a senior biotechnology research analyst at Robertson Stephens from 1989 to 2002. He began his career at Kidder Peabody. Mr. Simon is a strategic advisor to Sun Pharma Advanced Research Company Limited, a public company in India. Mr. Simon formerly served on the boards of directors of ControlRad Systems from 2012 to 2019 and Hutchinson Water International Holdings Limited from 2014 to 2018. Mr. Simon also serves on the board of several disease advocacy and philanthropic foundations. He received his M.B.A. from Harvard Business School and his B.A. from Columbia College.

Chair

Catherine Bollard, M.D.

Dr. Bollard joined Cabaletta’s Board of Directors in April 2019. She is the director of the Center for Cancer and Immunology Research at the Children’s Research Institute and the director of the Program for Cell Enhancement and Technologies for Immunotherapy at the Children’s National Health System, or CNH. She is also a faculty member of the Division of the Blood and Marrow Transplantation of CNH. Since 2013, Dr. Bollard also serves as Professor of Pediatrics and Microbiology, Immunology, and Tropical Medicine at George Washington University and is the associate center director for translational research and innovation within the George Washington Cancer Center. Prior to 2013, Dr. Bollard was Professor of Pediatrics, Medicine, and Immunology at Baylor College of Medicine. She is the immediate past president of the International Society for Cell Therapy, and she served on the Cellular, Tissues, and Gene Therapy Advisory Committee of the FDA until 2019. Dr. Bollard chaired the Non-Hodgkin’s Lymphoma Committee of the Children’s Oncology Group from 2012 to 2020 and in 2021 became the President of the Foundation for the Accreditation of Cellular Therapy. Dr. Bollard received her medical degree from the University of Otago Medical School in New Zealand.

Member

Richard Henriques, M.B.A.

Mr. Henriques joined Cabaletta’s Board of Directors in February 2019. Since 2015, he has been a senior fellow at the Center for High Impact Philanthropy at the University of Pennsylvania, with a focus on impact investing. From 2010 to 2014, Mr. Henriques was the chief financial officer of the Bill & Melinda Gates Foundation, where he was responsible for finance and accounting, financial planning and analysis, strategic planning, measurement and evaluation, program-related investments, and information technology. From 1981 to 2008, Mr. Henriques held positions at Merck & Co., Inc., including as Senior Vice President of Finance for Global Human Health, Vice President and Corporate Controller, and Principal Accounting Officer. Mr. Henriques also serves on the boards of directors of Emulate Therapeutics Inc. (formerly Nativis Inc.), Arbutus Biopharma Corporation, a public company, the Heritage Conservancy and Episcopal Community Services and on the board of trustees of the Franklin Institute.

Member

Nominating and Corporate Governance Committee Charter

Download

Richard Henriques, M.B.A.

Mr. Henriques joined Cabaletta’s Board of Directors in February 2019. Since 2015, he has been a senior fellow at the Center for High Impact Philanthropy at the University of Pennsylvania, with a focus on impact investing. From 2010 to 2014, Mr. Henriques was the chief financial officer of the Bill & Melinda Gates Foundation, where he was responsible for finance and accounting, financial planning and analysis, strategic planning, measurement and evaluation, program-related investments, and information technology. From 1981 to 2008, Mr. Henriques held positions at Merck & Co., Inc., including as Senior Vice President of Finance for Global Human Health, Vice President and Corporate Controller, and Principal Accounting Officer. Mr. Henriques also serves on the boards of directors of Emulate Therapeutics Inc. (formerly Nativis Inc.), Arbutus Biopharma Corporation, a public company, the Heritage Conservancy and Episcopal Community Services and on the board of trustees of the Franklin Institute.

Brian Daniels, M.D.

Dr. Daniels joined Cabaletta’s Board of Directors in October 2018. Since 2018, he has been a partner at 5AM Ventures, where he was previously a venture partner from 2014 to 2018. From 2004 to 2014, Dr. Daniels held positions at Bristol-Myers Squibb, serving as senior vice president, global development and medical affairs from 2004 to 2014. Dr. Daniels also serves on the boards of directors of Nohla Therapeutics Inc., and Novo Nordisk A/S, and on the clinical advisory board of Aprea Therapeutics AB. He previously served on the boards of directors of Spyryx Biosciences, Inc., RareCyte, Inc., and IDEAYA Biosciences, Inc. Dr. Daniels received his M.D. from Washington University in St. Louis and his B.S. and M.S. from Massachusetts Institute of Technology. He completed his residency in Internal Medicine at New York Hospital and a fellowship in Rheumatology and Immunology at the University of California, San Francisco.

Mark Simon, M.B.A.

Mr. Simon joined Cabaletta’s Board of Directors in October 2018. He is a partner and co-founder of, and advisor to, Torreya Partners, LLC, a global investment banking firm serving companies in the life sciences industry. Prior to co-founding Torreya, Mr. Simon was a managing director and head of life sciences investment banking at Citigroup from 2002 to 2005, and a senior biotechnology research analyst at Robertson Stephens from 1989 to 2002. He began his career at Kidder Peabody. Mr. Simon is a strategic advisor to Sun Pharma Advanced Research Company Limited, a public company in India. Mr. Simon formerly served on the boards of directors of ControlRad Systems from 2012 to 2019 and Hutchinson Water International Holdings Limited from 2014 to 2018. Mr. Simon also serves on the board of several disease advocacy and philanthropic foundations. He received his M.B.A. from Harvard Business School and his B.A. from Columbia College.

Brian Daniels, M.D.

Dr. Daniels joined Cabaletta’s Board of Directors in October 2018. Since 2018, he has been a partner at 5AM Ventures, where he was previously a venture partner from 2014 to 2018. From 2004 to 2014, Dr. Daniels held positions at Bristol-Myers Squibb, serving as senior vice president, global development and medical affairs from 2004 to 2014. Dr. Daniels also serves on the boards of directors of Nohla Therapeutics Inc., and Novo Nordisk A/S, and on the clinical advisory board of Aprea Therapeutics AB. He previously served on the boards of directors of Spyryx Biosciences, Inc., RareCyte, Inc., and IDEAYA Biosciences, Inc. Dr. Daniels received his M.D. from Washington University in St. Louis and his B.S. and M.S. from Massachusetts Institute of Technology. He completed his residency in Internal Medicine at New York Hospital and a fellowship in Rheumatology and Immunology at the University of California, San Francisco.

Catherine Bollard, M.D.

Dr. Bollard joined Cabaletta’s Board of Directors in April 2019. She is the director of the Center for Cancer and Immunology Research at the Children’s Research Institute and the director of the Program for Cell Enhancement and Technologies for Immunotherapy at the Children’s National Health System, or CNH. She is also a faculty member of the Division of the Blood and Marrow Transplantation of CNH. Since 2013, Dr. Bollard also serves as Professor of Pediatrics and Microbiology, Immunology, and Tropical Medicine at George Washington University and is the associate center director for translational research and innovation within the George Washington Cancer Center. Prior to 2013, Dr. Bollard was Professor of Pediatrics, Medicine, and Immunology at Baylor College of Medicine. She is the immediate past president of the International Society for Cell Therapy, and she served on the Cellular, Tissues, and Gene Therapy Advisory Committee of the FDA until 2019. Dr. Bollard chaired the Non-Hodgkin’s Lymphoma Committee of the Children’s Oncology Group from 2012 to 2020 and in 2021 became the President of the Foundation for the Accreditation of Cellular Therapy. Dr. Bollard received her medical degree from the University of Otago Medical School in New Zealand.

Mark Simon, M.B.A.

Mr. Simon joined Cabaletta’s Board of Directors in October 2018. He is a partner and co-founder of, and advisor to, Torreya Partners, LLC, a global investment banking firm serving companies in the life sciences industry. Prior to co-founding Torreya, Mr. Simon was a managing director and head of life sciences investment banking at Citigroup from 2002 to 2005, and a senior biotechnology research analyst at Robertson Stephens from 1989 to 2002. He began his career at Kidder Peabody. Mr. Simon is a strategic advisor to Sun Pharma Advanced Research Company Limited, a public company in India. Mr. Simon formerly served on the boards of directors of ControlRad Systems from 2012 to 2019 and Hutchinson Water International Holdings Limited from 2014 to 2018. Mr. Simon also serves on the board of several disease advocacy and philanthropic foundations. He received his M.B.A. from Harvard Business School and his B.A. from Columbia College.

Mark Simon, M.B.A.

Mr. Simon joined Cabaletta’s Board of Directors in October 2018. He is a partner and co-founder of, and advisor to, Torreya Partners, LLC, a global investment banking firm serving companies in the life sciences industry. Prior to co-founding Torreya, Mr. Simon was a managing director and head of life sciences investment banking at Citigroup from 2002 to 2005, and a senior biotechnology research analyst at Robertson Stephens from 1989 to 2002. He began his career at Kidder Peabody. Mr. Simon is a strategic advisor to Sun Pharma Advanced Research Company Limited, a public company in India. Mr. Simon formerly served on the boards of directors of ControlRad Systems from 2012 to 2019 and Hutchinson Water International Holdings Limited from 2014 to 2018. Mr. Simon also serves on the board of several disease advocacy and philanthropic foundations. He received his M.B.A. from Harvard Business School and his B.A. from Columbia College.

Catherine Bollard, M.D.

Dr. Bollard joined Cabaletta’s Board of Directors in April 2019. She is the director of the Center for Cancer and Immunology Research at the Children’s Research Institute and the director of the Program for Cell Enhancement and Technologies for Immunotherapy at the Children’s National Health System, or CNH. She is also a faculty member of the Division of the Blood and Marrow Transplantation of CNH. Since 2013, Dr. Bollard also serves as Professor of Pediatrics and Microbiology, Immunology, and Tropical Medicine at George Washington University and is the associate center director for translational research and innovation within the George Washington Cancer Center. Prior to 2013, Dr. Bollard was Professor of Pediatrics, Medicine, and Immunology at Baylor College of Medicine. She is the immediate past president of the International Society for Cell Therapy, and she served on the Cellular, Tissues, and Gene Therapy Advisory Committee of the FDA until 2019. Dr. Bollard chaired the Non-Hodgkin’s Lymphoma Committee of the Children’s Oncology Group from 2012 to 2020 and in 2021 became the President of the Foundation for the Accreditation of Cellular Therapy. Dr. Bollard received her medical degree from the University of Otago Medical School in New Zealand.

Richard Henriques, M.B.A.

Mr. Henriques joined Cabaletta’s Board of Directors in February 2019. Since 2015, he has been a senior fellow at the Center for High Impact Philanthropy at the University of Pennsylvania, with a focus on impact investing. From 2010 to 2014, Mr. Henriques was the chief financial officer of the Bill & Melinda Gates Foundation, where he was responsible for finance and accounting, financial planning and analysis, strategic planning, measurement and evaluation, program-related investments, and information technology. From 1981 to 2008, Mr. Henriques held positions at Merck & Co., Inc., including as Senior Vice President of Finance for Global Human Health, Vice President and Corporate Controller, and Principal Accounting Officer. Mr. Henriques also serves on the boards of directors of Emulate Therapeutics Inc. (formerly Nativis Inc.), Arbutus Biopharma Corporation, a public company, the Heritage Conservancy and Episcopal Community Services and on the board of trustees of the Franklin Institute.